Printer Friendly

Lucentis Macular Edema and Degeneration Treatment Market Analysis and Forecast to 2023.

DALLAS, March 19, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Lucentis (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" market research report provides detailed information on Lucentis including product description, safety and efficacy profiles as well as a SWOT analysis.

Lucentis (ranibizumab) is an anti-VEGF-A monoclonal antibody (mAb) fragment developed by Genentech/Roche. It is derived from the larger parent molecule, bevacizumab, which is another anti-VEGF drug marketed as Avastin by Genentech/Roche/Chugai. It was hoped that Lucentis, as a lower-molecular-weight, humanized fragment of an immunoglobulin G1 (IgG1) mAb, would result in improved retinal penetration over Avastin, and therefore, confer superior efficacy. Complete report is available at http://www.rnrmarketresearch.com/lucentis-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023-market-report.html.

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of macular edema are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the macular edema and age-related macular degeneration markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry age-related macular degeneration, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet age-related macular degeneration adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Scope

* Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

* Detailed information on Lucentis including product description, safety and efficacy profiles as well as a SWOT analysis.

* Sales forecast for Lucentis for the top seven countries from 2013 to 2023.

* Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=312778. (This is a premium report priced at US$3495 for a single user License.)

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return.

* Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.

* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

* Make more informed business decisions from insightful and in-depth analysis of Lucentis performance.

* Obtain sales forecast for Lucentis from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Explore more reports of Ophthalmology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ophthalmology-therapeutics.

Related reports on Ophthalmology therapeutics:

Eylea (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Eylea (aflibercept) is a recombinant fusion protein co-developed by Regeneron and Bayer AG. Eylea acts as a VEGF inhibitor and is approved for the treatment of wAMD and ME-CRVO in all 7MM, and for DME in the US and EU. The developers are also attempting to gain approval for Eylea for DME in Japan, and for ME-BRVO throughout in the EU and Japan. Complete report available at http://www.rnrmarketresearch.com/eylea-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023-market-report.html.

Visudyne (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Visudyne (verteporfin) is a photosensitizer molecule that was co-developed by QLT PhotoTherapeutics and Novartis Pharma AG for use in a two-step procedure involving the use of a non-thermal laser light, known as PDT. It was initially approved by the FDA in April 2000 for the treatment of patients with predominantly classical subfoveal CNV due to AMD. Complete report available at http://www.rnrmarketresearch.com/remicade-infliximab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html.

Fovista (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Fovista is a first-in-class anti-platelet-derived growth factor (anti-PDGF) agent being developed by Ophthotech for the treatment of wAMD as a combination therapy with an anti-VEGF drug, such as Lucentis, Avastin, or Eylea. The company is currently conducting a Phase III clinical program consisting of three large trials that are investigating the efficacy of Fovista combination therapy with anti-VEGF agents in comparison with anti-VEGF monotherapy, which is the current standard of care across the 7MM. Complete report available at http://www.rnrmarketresearch.com/fovista-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023-market-report.html.

Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Lampalizumab, also known as anti-factor D (as well as RG7417 by Roche and as FCFD4514S by its subsidiary, Genentech), is an antigen-binding fragment of a humanized mAb that targets complement factor D, the rate-limiting enzyme involved in the activation of the alternative complement pathway. Complete report available at http://www.rnrmarketresearch.com/lampalizumab-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023-market-report.html.

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact: Ritesh Tiwari TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441 sales@rnrmarketresearch.com
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Mar 19, 2015
Words:1152
Previous Article:Oil & Gas Subsea Umbilicals, Risers & Flowlines (SURF) Market 2015-2025.
Next Article:Movado Group, Inc. Launches Innovative New Watch Collections At Baselworld 2015.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters